P065 VEDOLIZUMAB RELATED INFUSION REACTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED IN AN ALTERNATE CARE SETTING

作者
L. Allyson Checkley,Loretta Kristofek,William Bolgar
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
卷期号:25 (Supplement_1): S31-S31 被引量:2
标识
DOI:10.1093/ibd/izy393.071
摘要

Several studies have indicated that home infusions of biologic agents are safe for selected patients with inflammatory bowel disease. Vedolizumab is a monoclonal antibody directed against the α4β7 integrin and is indicated for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in patients that have had an inadequate response to or demonstrated intolerability to corticosteroids, immunomodulators, or TNF-α inhibitors. Its novel GI-selective target suggests that associated adverse events may differ than those in older biologics. The purpose of this study was to determine the incidence and severity of acute vedolizumab infusion reactions in an alternate site of care. A retrospective chart review was conducted identifying IBD patients who received vedolizumab with one home infusion provider in the home or company Ambulatory Infusion Suite (AIS) between January 2014 and November 2016. Incidence and management of acute IRs were analyzed. IRs that occurred during or within 24 hours of the infusion were considered acute. Reactions were categorized as mild (i.e. transient pruritus, flushing), moderate (i.e. urticaria, dyspnea) or severe (i.e. bronchospasms, angioedema, infusion discontinued, ER visit). A total of 126 infusions administered in 25 patients (16 with ulcerative colitis and 9 with Crohn’s disease) were analyzed. Seventeen patients were female, and the mean age of the patient population was 35.1 years. There was 1 acute IR recorded for a per-infusion reaction rate of 0.8% and a per-patient reaction rate of 4.0%. The reaction consisted of severe nausea and pallor resulting in discontinuance of the infusion. The patient was driven to the ER by a family member. This infusion reaction occurred on the patient’s 22nd maintenance infusion with vedolizumab. Of note, this patient experienced several ulcerative colitis symptom flare-ups in the two-weeks prior to infusion. This patient had tried aminosalicylates and infliximab prior to initiation of vedolizumab and was transitioned due to lack of therapy response and infliximab-related infusion reactions. The reaction did not lead to discontinuation of future vedolizumab infusions. Vedolizumab infusion reactions are rare in an alternate-care setting and may provide a safe alternative to patients intolerant or unresponsive to TNF-alpha inhibitors. Large-scale future studies are needed to identify factors associated with acute infusion reactions to vedolizumab and determine any preventive measures.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
专注的玉米完成签到,获得积分10
刚刚
Planck完成签到,获得积分10
刚刚
麦穗完成签到,获得积分10
刚刚
刻苦安露完成签到,获得积分10
刚刚
月九完成签到,获得积分10
刚刚
yKkkkkk完成签到,获得积分10
刚刚
雾醉舟完成签到,获得积分10
刚刚
skmksd发布了新的文献求助10
1秒前
2秒前
bl完成签到,获得积分10
2秒前
chenzhuod完成签到,获得积分10
3秒前
读书看报吃饭睡觉完成签到,获得积分10
3秒前
3秒前
大约在冬季完成签到,获得积分10
3秒前
斯文败类的应助被369ninja采纳,获得10
4秒前
星辰大海的应助被倬琸采纳,获得10
4秒前
深情安青的应助被snjxh采纳,获得10
5秒前
瀼瀼完成签到,获得积分10
5秒前
淦淦淦完成签到 ,获得积分10
5秒前
ml完成签到 ,获得积分10
5秒前
一氧化二氢完成签到,获得积分10
5秒前
小虫完成签到,获得积分10
5秒前
Helen完成签到,获得积分10
6秒前
安静怜雪完成签到,获得积分10
6秒前
刘较瘦完成签到,获得积分10
6秒前
好运爆彭完成签到,获得积分10
7秒前
樊小雾完成签到,获得积分10
7秒前
Qinzhiyuan1990完成签到 ,获得积分10
7秒前
爱科研的Z完成签到,获得积分10
8秒前
princesun083完成签到,获得积分10
8秒前
ZeKaWa的应助被发呆采纳,获得10
8秒前
玩命的灵安完成签到,获得积分10
8秒前
科研通AI65的应助被月九采纳,获得10
9秒前
9秒前
汉堡包的应助被完美的映秋采纳,获得30
9秒前
10秒前
zhugeliu完成签到,获得积分10
10秒前
skmksd完成签到,获得积分10
10秒前
QIEZI完成签到 ,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039